Home > Boards > Free Zone > Health and Sciences > Biotech Values

<u>Demystifying ABBV/ENTA&rsquo;s SAPHIRE-1/2 Trials</u>

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 754
Posts 116,260
Boards Moderated 10
Alias Born 09/05/02
160x600 placeholder
Truist Financial Raises Quarterly Cash Dividend
Truist Financial Corp. on Tuesday said its board raised the company's regular quarterly cash dividend by 7%.
Mondelez: Currency Translations to Boost Full-Year Revenue Growth -- Currency Comment
Visa Profit, Net Revenue Climbs with Payments Volume Increasing
Mondelez Raises Fiscal Year Organic Net Revenue Growth Outlook
U.S. Crude-Oil Stockpiles Likely to Fall in DOE Data, Analysts Say -- Update
Top Company News of the Day
Stryker Swings to 2Q Profit as Pandemic Moderated
Starbucks Says Foreign Exchange Rates Boosted 3Q Revenue -- Currency Comment
AMD Raises Revenue Guidance Following Better-than-Expected 2Q Performance
Mondelez 2Q Profit Nearly Doubles As Sales Rise on Consumer Demand
ObsEva Shares Climb 10% on Licensing Deal With Organon
Wheat Slides as Traders Take Tentative Stance -- Daily Grain Highlights
Front Month Nymex RBOB Gasoline Rose 0.25% to Settle at $2.3141 -- Data Talk
Front Month Nymex Natural Gas Fell 3.19% to Settle at $3.9710 -- Data Talk
Boston Scientific Third Best Performer in the S&P 500 So Far Today -- Data Talk
Shell New Energies to Buy Inspire Energy Capital
Yum China Down Over 6%, on Pace for Largest Percent Decrease Since May 2020 -- Data Talk
Rio Tinto Commits $2.4 Billion to Serbian Lithium Project
Europcar Confirms Advanced Takeover Talks With Volkswagen Consortium
Rio Tinto Commits $2.4 Billion to Lithium Project in Serbia -- Commodity Comment
Casino, Credit Mutuel to Sell Payment Provider to BNP Paribas for EUR258 Million
DewDiligence Member Level  Thursday, 09/05/13 09:28:52 PM
Re: DewDiligence post# 164591
Post # of 238823 
Demystifying ABBV/ENTA’s SAPHIRE-1/2 Trials

ABBV/ENTA’s SAPHIRE-1 and -2 are likely to be the first two phase-3 trials of the nine (!) phase-3 trials including ABT-450 to report data (see #msg-90408583 for a description of all nine trials). What some investors may not realize is that SAPHIRE-1 and -2 are essentially safety trials insofar as there is no bona fide control arm for an efficacy comparison.

In SAPHIRE-1 and -2, half of the patients are randomized to immediately receive ABBV’s 5-drug cocktail (ABT-450, ABT-267/r, ABT-333, and ribavirin) for 12 weeks; the other half of the patients are randomized to receive only placebos for 12 weeks followed by the identical 5-drug regimen as the first arm for 12 weeks (http://www.clinicaltrials.gov/ct2/show/NCT01716585 , http://www.clinicaltrials.gov/ct2/show/NCT01715415 ).

Because HCV progresses relatively slowly and a patient’s condition does not deteriorate materially without treatment during a period as short as 12 weeks, SAPHIRE-1 and -2 have essentially no difference between the two trial arms with respect to efficacy.

With respect to safety, however, the control (i.e. delayed-treatment) arm can serve as a comparator to the immediate-treatment arm to establish the safety profile of ABBV/ENTA’s regimen, relative to placebo, during the 12-week treatment period.

Note: The only difference between SAPHIRE-1 and SAPHIRE-2 is that the former is for treatment-naïve patients and the latter is for treatment-experienced patients. All patients in both trials are genotype-1.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences